
A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

The instrument’s score was compared favorably to the Dermatology Life Quality Index and Vitiligo Impact Patient score.

Volume of waiting list registrations and DDLTs for alcoholic hepatitis exceeded expected trends by a mean of 59.5% in waiting list registrations and 62.0% in DDLTs

Investigators noted that despite these self-reported allergic reactions, they were not an impediment for the completion of the 2-dose vaccination series.

An increase in benzodiazepine prescriptions in women patients was also reported, which suggested a substantial mental health impact of COVID-19-associated mitigation measures.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

To date, dupilumab is the only medicine to show clinically meaningful phase 3 results in this patient population, with regulatory fillings planned for 2022.

Data show women with AMI exhibited a more adverse cardiac risk factor profile and were more socially vulnerable than men in the US compared to Canada.

Triamcinolone acetonide injectable suspension has been approved for administration via the suprachoroidal pathway—located in the back of the eye.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Data show In youth with obesity, but not healthy weight, visceral fat was positively associated with PWV and was predictive of PWV beyond BMI and waist circumference.

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.

In the full interview with Dr. Fasipe, she challenges healthcare professionals to step up their understanding of sickle cell disease and the complications that patients are facing when they seek help.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

The novel PDS implant will allow patients with retina disease to receive continuous anti-VEGF formulation for up to 6 months between refills.

In older patients receiving medication intensification, no differences were seen in the risk of severe hyperglycemia, severe hypoglycemia, or death at 1 year.

Though high-dose ultraviolet therapy was also effective, investigators were concerned with the potential long-term adverse events.

This represents the first biologic to show positive phase 3 results in prurigo nodularis.

Lactate dehydrogenase levels were significantly higher in patients with Influenza A.

The REVEAL Lite 2 risk assessment tool confirmed that treatment with the agonist improved risk profile and long-term outcomes of patients with pulmonary arterial hypertension.